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ttp://dx.doi.org/10.1016/j.ajpath.2013.04.003Chitinase 1 (CHIT1) is secreted by activated macrophages. Chitinase activity is raised in atherosclerotic
patient sera and is present in atherosclerotic plaque. However, the role of CHIT1 in atherosclerosis is
unknown. Preliminary studies of atherosclerosis in cynomolgous monkeys revealed CHIT1 to be closely
correlated with areas of macrophage inﬁltration. Thus, we investigated the effects of a chitinase inhibitor,
allosamidin, onmacrophage function in vitro and on atherosclerotic development in vivo. In RAW264.7 cells,
allosamidin elevated monocyte chemoattractant protein 1 and tumor necrosis factor alpha expression, and
increased activator protein 1 and nuclear factor-kB transcriptional activity. Although inducible nitric oxide
synthase, IL-6, and IL-1b expression were increased, Arg1 expression was decreased by chitinase inhibition,
suggesting that suppression of CHIT1 activity polarizes macrophages into a M1 phenotype. Allosamidin
decreased scavenger receptor AI, CD36, ABCA1, and ABCG1 expression which led to suppression of
cholesterol uptake and apolipoprotein AI-mediated cholesterol efﬂux in macrophages. These effects were
conﬁrmed with CHIT1 siRNA transfection and CHIT1 plasmid transfection experiments in primary macro-
phages. Apolipoprotein E-deﬁcient hyperlipidemic mice treated for 6 weeks with constant administration of
allosamidin and fed an atherogenic diet showed aggravated atherosclerotic lesion formation. These data
suggest that CHIT1 exerts protective effects against atherosclerosis by suppressing inﬂammatory responses
and polarizing macrophages toward an M2 phenotype, and promoting lipid uptake and cholesterol efﬂux in
macrophages. (Am J Pathol 2013, 183: 313e325; http://dx.doi.org/10.1016/j.ajpath.2013.04.003)Supported by a Grant-in-Aid for Young Scientists (17102) from the
Ministry of Education, Culture, Sports, Science and Technology of Japan,
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Hawaii Community Foundation (10ADVC-47037) (W.A.B.).Atherosclerosis is characterized by excessive lipid accumula-
tion and chronic inﬂammation within the arterial wall.1 When
risk factors such as hyperlipidemia and hypertension are pre-
sented, vascular endothelial cells are stimulated to express
adhesion molecules, which promote attachment of circulating
leukocytes. Concomitantly, increased endothelial permeability
allows deposition of cholesterol-containing lipoproteins in the
intima. These lipoproteins can become biologically or chem-
ically modiﬁed and stimulate surrounding cells to express
chemokines such as monocyte chemoattractant protein 1
(MCP-1), which can induce further leukocyte migration into
the vascular wall. Monocytes are one of the ﬁrst leukocytes
to transmigrate and differentiate into macrophages, which are
the predominant immune cells observed in atherosclerotic
lesions, especially in the early stages. Macrophages possess anstigative Pathology.
.unlimited propensity to take up accumulated modiﬁed lipo-
proteins such as oxidized low density lipoprotein via scav-
enger receptors (SR) and thereby get transformed into
cholesterol-rich foam cells that make up the majority of the
Kitamoto et alearly fatty streaks. Macrophages activated by modiﬁed lipo-
proteins produce pro-inﬂammatory cytokines, including IL-1b
and tumor necrosis factor a (TNFa), which can mediate
inﬂammation in the arterial wall and cause subsequent inﬁl-
tration of T lymphocytes that may further accelerate inﬂam-
mation in the lesion. Activated macrophages also produce
reactive oxygen species, matrix metalloproteinases that
degrade extracellular matrix, and the procoagulant tissue
factor, which induce subsequent plaque rupture and throm-
bogenesis.2 Thus, macrophages play a pivotal role in the
pathogenesis of lesion formation throughout all stages of
atherosclerosis.
The enzyme chitotriosidase [chitinase 1 (CHIT1)] is
a member of the glycosyl hydrolase family 18, which
cleaves its substrate, chitin.3 Chitin is a polymer of b-1,
4-N-acetyl-glucosamine, which is produced by many living
organisms including insects, fungi, crustaceans, and other
marine organisms. Interestingly, despite the absence of
chitin in mammals, CHIT1 is abundantly produced by
activated macrophages in various human diseases, including
Gaucher disease and Niemann-Pick disease. It has also been
reported that chitinase activity is elevated up to 55-fold in
human atherosclerotic tissue.4 Moreover, serum chitinase
activity is elevated in patients with atherosclerosis and is
associated with the severity of atherosclerotic lesions.5
Similarly, when we performed a comprehensive gene
expression analysis by DNA microarray assay, we found
a tight correlation between CHIT1 mRNA expression and
areas of macrophage inﬁltration in atherosclerotic lesions of
cynomolgus monkeys. However, little is known about the
physiological role of CHIT1 in the pathogenesis of athero-
sclerosis. In this study, we investigated the effects of a chi-
tinase inhibitor, allosamidin,6 on macrophage function and
atherosclerotic lesion development to speculate how CHIT1
activity might function in atherosclerosis.
Materials and Methods
Cell Culture
The mouse macrophage cell line RAW264.7 (American
Type Culture Collection, Rockville, MD) was cultured in
Dulbecco’s modiﬁed Eagle’s medium (DMEM) supple-
mented with 10% fetal calf serum, penicillin (50 U/mL),
streptomycin (50 mg/mL), and L-glutamine (2 mmol/L).
Cells were kept at subconﬂuence in a humidiﬁed incubator
at 37C with 5% CO2. RAW264.7 cells were treated with
10 mmol/L allosamidin to inhibit chitinase activity. Bone
marrowederived macrophages (BMDM) from C57BL/6
mice were generated by ﬂushing the femurs of mice.7 After
centrifugation at 300  g, the cells were resuspended in
macrophage growth medium consisting of DMEM and 10%
fetal bovine serum, and were supplemented with 20% (v/v)
L929 cell conditioned medium as a source of colony-
stimulating factor, penicillin (100 U/mL) and streptomycin
(100 mg/mL). Fibroblasts were allowed to adhere for 4314hours at 37C and then nonadherent cells were transferred to
another ﬂask. This step was repeated after overnight incu-
bation at 37C. On day 8, most of the adherent cells were
macrophages (>98% MAC1-positive cells and 99%
phagocytosis activity). Isolated BMDM were stimulated
with acetylated low density lipoprotein (Ac-LDL, 50 mg/
mL) (Life Technologies, Grand Island, NY); monocyte
chemoattractant protein-1 (MCP-1, 100 ng/mL, R&D
Systems, Minneapolis, MN); lipopolysaccharide (LPS, 100
ng/mL) (Sigma-Aldrich, St. Louis, MO); advanced glyca-
tion end product bovine serum albumin (AGE-BSA, 100
mg/mL, Calbiochem, La Jolla, CA); or interferon gamma
(IFNg) (100 units/mL, eBioscience, San Diego, CA). The
cells were also treated with 20 mmol/L allosamidin or
vehicle control  10 units/mL IFN-g, and used for the
CHIT1 plasmid transfection study. Thioglycollate-elicited
peritoneal macrophages were obtained from male C57BL/6
mice by standard method. In brief, mice were injected
intraperitoneally with 1 mL of 3% Brewer thioglycollate
medium (Becton Dickinson, Franklin Lakes, NJ). Four days
later, the peritoneal cells were harvested by lavage with cold
PBS and plated on petri dishes. The cells were allowed to
adhere for 4 hours and washed with PBS to remove non-
adherent cells before being used for the siRNA transfection
study.
Chitinase Activity Assay
Chitinase activity assay was performed using 4-
methylumbelliferyl-N, N0, N00-triacetyl chitotrioside [4MU-
(GlcNAc)3] (Sigma-Aldrich, St. Louis, MO) as a substrate.
8
A solution of 25 mmol/L 4MU-(GlcNAc)3 in N, N-dime-
thylformamide was diluted 1:500 with distilled water, and the
resulting solution (40 mL) was added to 0.5, 2, or 4 mL
mixture of the culture ﬁltrate in each experiment along with
50 mmol/L citric acid (50 mmol/L Na2HPO4 buffer; pH 5.0;
100 mL). After incubating the mixture at 28.5C for
60 minutes, the reaction was stopped by adding 1.0 M
glycine (NaOH buffer; pH 10.5; 2.5 mL), and the liberated
4-methylumbelliferone was measured with a ﬂuorescence
spectrometer (excitation at 360 nm, emission at 450 nm).
The value of ﬂuorescence strength was used for calibra-
tion of relative chitinase activity or calculation of abso-
lute chitinase activity (U/mL) by referring to standard
4-methylumbelliferone solution. [Unit deﬁnition: One unit
will release 1.0 mmole of 4-methylumbelliferone from
4MU-(GlcNAc)3 per minute].
RNA Extraction and Real-Time RT-qPCR
Total cellular RNA was extracted from cells using TRIzol
(Invitrogen, San Diego, CA), according to the recommended
procedure. Real-time quantitative RT-PCR (real-time RT-
qPCR) was performed using the ABI Prism 7700 (Applied
Biosystems, Foster City, CA) SYBR Green analysis. The
sequence-speciﬁed PCR primers used in these experimentsajp.amjpathol.org - The American Journal of Pathology
Table 1 Sequence-Speciﬁc PCR Primers Used for Real-Time RT-qPCR
Gene name Primers
GAPDH Forward 50-GGCAAATTCAACGGCACAGT-30
Reverse 50-CGCTCCTGGAAGATGGTGAT-30
CHIT1 Forward 50-CGTCATCTTTGCTTTTGCTGG-30
Reverse 50-TGGTAGAGAAGTTCGTCATTGTGC-30
MCP-1 Forward 50-TCACTGAAGCCAGCTCTCTCT-30
Reverse 50-GTGGGGCGTTAACTGCAT-30
TNFa Forward 50-CTGTAGCCCACGTCGTAG C-30
Reverse 50-GGTTGTCTTTGAGATCCATGC-30
CCR2 Forward 50-AGCACATGTGGTGAATCCAA-30
Reverse 50-TGCCATCATAAAGGAGCCA-30
CD36 Forward 50-CAAGCTCCTTGGCATGGTAGA-30
Reverse 50-TGGATTTGCAAGCACAATATGAA-30
SR-AI Forward 50-TTAAAGGTGATCGGGGACAAA-30
Reverse 50-CAACCAGTCGAACTGTCTTAAG-30
ABCA1 Forward 50-CCCAGAGCAAAAAGCGACTC-30
Reverse 50-GGTCATCATCACTTTGGTCCTTG-30
ABCG1 Forward 50-CAAGACCCTTTTGAAAGGGATCTC-30
Reverse 50-GCCAGAATATTCATGAGTGTGGAC-30
PPARg Forward 50-GTCACGTTCTGACAGGACTGTGTGAC-30
Reverse 50-TATCACTGGAGATCTCCGCCAACAGC-30
LXRa Forward 50-AGGAGTGTCGACTTCGCAAA-30
Reverse 50-CTCTTCTTGCCGCTTCAGTTT-30
iNOS Forward 50-CAAGCTGAACTTGAGCGAGGA-30
Reverse 50-TTTACTCAGTGCCAGAAGCTGGA-30
IL-6 Forward 50-CCACTTCACAAGTCGGAGGCTTA-30
Reverse 50-GCAAGTGCATCATCGTTGTTCATAC-30
IL-12p35 Forward 50-TGTCTTAGCCAGTCCCGAAACC-30
Reverse 50-TCTTCATGATCGATGTCTTCAGCAG-30
IL-1b Forward 50-TCCAGGATGAGGACATGAGCAC-30
Reverse 50-GAACGTCACACACCAGCAGGTTA-30
Arg1 Forward 50-AGCTCTGGGAATCTGCATGG-30
Reverse 50-ATGTACACGATGTCTTTGGCAGATA-30
FIZZ1 Forward 50-TCCAGCTGATGGTCCCAGTG-30
Reverse 50-GAGGCCCATCTGTTCATAGTCTTG-30
IL-10 Forward 50-GACCAGCTGGACAACATACTGCTAA-30
Reverse 50-GATAAGGCTTGGCAACCCAAGTAA-30
ABCA1, ATP-binding cassette transporter A1; GAPDH, glyceraldehyde-
3-phosphate dehydrogenase; iNOS, inducible nitric oxide synthase; LXRa,
liver X receptor a; PPARg, peroxisome proliferator-activated receptor g;
SR-AI, scavenger receptor AI.
Role of Chitinase in Atherosclerosisare listed in Table 1. The gene products were quantiﬁed
using SYBR Green assays (Applied Biosystems, Foster
City, CA) and glyceraldehyde-3-phosphate dehydrogenase
was used for normalization.
Electromobility Shift Assay
Cells were cultured on a 12-well plate overnight. For collec-
tion of nuclear protein, cells were rinsed with PBS, removed
from the plate with a cell scraper, transferred to a microfuge
tube, and centrifuged at 4000 rpm for 5 minutes. The cell
pellets were resuspended in 400 mL of cold 1 Solution A
buffer [10 mmol/L HEPES (pH 7.4), 10 mmol/L KCl,
1.5 mmol/L MgCl2, 0.5 mmol/L dithiothreitol, 0.4 mmol/L
phenylmethylsulfonyl ﬂuoride]. After resuspension, sam-
ples were incubated for 20 minutes on ice and vortexedThe American Journal of Pathology - ajp.amjpathol.orgfor 1 minute. Samples were centrifuged at 600  g for
10 minutes, and supernatant was completely removed.
Pellets were resuspended in 1 mL of Solution C buffer
containing 20 mmol/L HEPES (pH 7.4), 0.42 mmol/L NaCl,
1.5 mmol/L MgCl2, 0.5 mmol/L dithiothreitol, 0.4 mmol/L
phenylmethylsulfonyl ﬂuoride and were placed on ice for 20
minutes. Samples were spun at 13,000 rpm for 10 minutes,
and supernatants were transferred to a fresh tube. Protein
concentration was determined using the bicinchoninic acid
(BCA) Protein Assay Kit (Pierce, Rockford, IL)) per the
manufacturer’s directions. Nuclear factor-kB (NF-kB) and
activator protein 1 (AP-1) consensus oligomer (50 ng) (Santa
Cruz Biotechnology, Santa Cruz, CA) were labeled with
[g-32P] ATP using T4 polynucleotide kinase (TAKARA
BIO INC, Ohtsu, Japan). The sequence of each consensus
oligomer is described as follows. Nuclear protein (5 mg) was
reacted with 20,000 cpm of labeled oligomer in binding
buffer containing 20 mmol/L HEPES, 60 mmol/L KCl, 4%
Ficoll, 0.1 mg/mL bovine serum albumin (BSA), 2 mmol/L
dithiothreitol, and 0.1 mg/mL poly(dI-dC) (Roche, Basel,
Switzerland) on ice for 30 minutes and was analyzed on a 6%
acrylamide gel (80:1 ratio of acrylamide to bis-acrylamide).
Gels were dried and exposed to X-ray ﬁlm (Amersham,
Arlington Heights, IL). For cold competition, 100-fold
excess of unlabeled oligomer was added. The sequence of
each consensus oligomer was: NF-kB: 50-AGTTGAGGG-
GACTTTCCCAGGC-30 and AP-1: 50-CGCTTGATGACT-
CAGCCGGAA-30.
Reporter Gene Assay
2 105 RAW264.7 cells were prepared in a 24-well plate. The
cells were then transfected with 0.7 mg/well of AP-1 or NF-kB
promotereluciferase plasmid (Clontech) and 0.3 mg per well
of b-galactosidase gene driven by SV40 promoter-enhancer
sequence (Promega). The transfection was performed using
SuperFect transfection reagent according to the manufac-
turer’s instructions (Qiagen, Valencia, CA). After incubation
for 24 hours, cells were treated with 10 mmol/L of allosamidin
or control vehicle for 6 hours. The cells were washed twice
with phosphate-buffered saline, lyzed in 200 mL lysis buffer
(25 mmol/L Tris, pH 7.8, 2 mmol/L EDTA, 2 mmol/L DL-
dithiothreitol, 10% glycerol, and 1% Triton X-100), and
100 mL of lysate was used for luciferase activity assay in
a Lumat luminometer (LB 9501) (Berthold Technologies, Oak
Ridge, TN). The assay was started by adding 100 mL of 470
mmol/L luciferin to cell lysate, and integrated peak lumines-
cence was determined over a 55-second window after a 5-
second delay. The b-galactosidase activity in the same
sample was measured spectrophotometrically and used to
normalize the luciferase activity.
Binding and Uptake of AcLDL
To determine the receptor-speciﬁc binding and uptake,
ﬂuorescence-labeled acetylated LDL (DiI-AcLDL) was used315
Kitamoto et alas previously described.9 Cells seeded in a 12-well plate
or chamber slide were treated with allosamidin overnight
followed by incubation with DiI-AcLDL at 10 mg/mL in
medium for 2 hours at 37C. The media containing DiI-
AcLDL was removed from culture and the cells were
washed twice with probe-free media. Cells from 12-well plate
were analyzed using a FACScan ﬂow cytometer (Becton
Dickinson), and data were analyzed with the CellQuest Pro
version 5.1 (Becton Dickinson). Cells on the chamber slides
were observed under ﬂuorescence microscope.
Cholesterol Efﬂux Assay
RAW264.7 cells were seeded in a 24-well plate for incu-
bation overnight before being labeled with loading media
[DMEM/glutamine/p/s/10% lipoprotein-deﬁcient calf serum 1
mCi/mL (of [3H] cholesterol)] with or without 10 mmol/L
allosamidin for 36 hours. The cells were washed twice with
PBS, after which DMEM/glutamine/0.2% fatty acid-free BSA
 10 mmol/L allosamidin was added into each well and
incubated for 1 to 2 hours. The medium was then aspirated.
For apolipoprotein AI (apoAI) and high-density lipoprotein
(HDL)-independent cholesterol efﬂux assay, efﬂux medium
(DMEM/glutamine/0.2% fatty acid-free BSA,  10 mmol/L
allosamidin) without apoAI and HDL was added to one set of
wells. For apoAI or HDL-dependent cholesterol efﬂux assay,
efﬂux medium, as previously mentioned, along with 20 mg/
mL of apoAI or 50 mg/mL of HDL was added in another set
of wells. After incubation for 2 hours, 100 mL of media was
removed and transferred to 1.5 mL Eppendorf tube. Cell
debris was spun down by centrifuging for 5 minutes. The
supernatant was gently transferred to 5 mL counting ﬂuid to
measure radioactivity [as efﬂuxed cholesterol (5-minute
program)]. At the end of the experiment, 0.5 mL of 0.1 N
NaOH was added to lyze the cells by incubating for 5 hours at
room temperature, and 100 mL of cell lysate was transferred to
5 mL counting ﬂuid to measure radioactivity. ApoAI or HDL-
induced [3H] cholesterol efﬂux was measured as the fraction
of total radiolabeled cholesterol appearing in the medium in
the presence of apoAI or HDL after subtraction of values for
apoAI and HDL-free medium. ApoAI or HDL-mediated
efﬂux was determined using the following formula: i)
percentage of efﬂux Z efﬂux/total labeled cholesterol; ii)
apoAI or HDL speciﬁc efﬂux Z percentage of efﬂux (with
apoAI or HDL)  the percentage of efﬂux (without apoAI
and HDL); and iii) percentage of increase in apoAI or HDL-
mediated efﬂux Z percentage (apoAI or HDL-speciﬁc
efﬂux)/percentage of efﬂux (without apoAI and HDL).
siRNA Transfection
Thioglycollate-elicited peritoneal macrophages were trans-
fected with Dharmacon siGENOME SMARTpool siRNA
(Thermo Fisher Scientiﬁc, Fife, WA) against mouse CHIT1 or
siGENOME nontargeting siRNA pool using lipofectamine
siRNAMax (Invitrogen), according to the manufacturer’s316instructions (ﬁnal RNA interference duplex concentration,
20 nmol/L). After 48 hours of transfection, the cells were har-
vested for mRNA extraction and real-time RT-qPCR was
performed.
CHIT1 Gene Transfection
Total mRNA was extracted from the mouse tongue using
TRIzol, and mouse CHIT1 cDNA was ampliﬁed by using
real-time PCR using two primers speciﬁc for the mouse
Chit1 gene (the sense primer: 50-ACAGAGCTGATA-
TCCCCAGAGCCT-30; the antisense primer: 50-TGGA-
GTTGGATGGGGTTCCAGG-30). The cDNA fragment
was cloned into the pTAC-2 TA cloning vector (BioDy-
namics, Tokyo, Japan) and was further subcloned into the
eukaryotic expression vector pcDNA3.1 plasmid. After-
ward, BMDM were transfected with control pcDNA3.1 or
pcDNA3.1-CHIT1 plasmid using MicroPorator MP-100
(Digital Bio Technology Co., Ltd., Seoul, Korea) accord-
ing to the manufacturer’s instructions. In brief, the cells
were resuspended in Neon resuspension buffer R (Invi-
trogen) containing pcDNA3.1 or pcDNA3.1-CHIT1
plasmid (6 million cells per DNA, 8 mg/100 mL) and were
pulsed twice with a voltage of 800 V and a width of 50
msec using a 100 mL Neon tip (Invitrogen). The cells were
then quickly transferred into two 6 cm cell culture plates
containing DMEM supplemented with 10% fetal bovine
serum. After 48 hours of transfection, the cells were stim-
ulated with or without 10 units/mL IFN-g for 6 hours and
harvested for mRNA extraction, and real-time RT-qPCR
was performed.
Animal Models
Ten week old male apolipoprotein E (ApoE )-knockout mice
(Jackson Laboratory, Bar Harbor, ME) were fed a chow diet
or a high fat diet containing 35% (w/w) fat and 1%
cholesterol (KBT Oriental Co., Ltd., Tosu, Saga, Japan)
with 1.9 mg/kg per day infusion of angiotensin II by
osmotic mini pump model 2004 (ALZET, Cupertino, CA)
for 4 weeks, and the descending aortas were harvested.
Total mRNA was extracted from the aortas and CHIT1
mRNA expression was evaluated by real-time RT-qPCR.
For the atherosclerotic mouse model of CHIT1 inhibition,
spontaneous hyperlipidemic C57BL/6.KOR/Stm Slc-Apoeshl
mice, deﬁcient in ApoE expression, were obtained from Japan
SLC Inc. (Shizuoka, Japan).10 Mice (12-weeks-old) were
implanted subcutaneously with osmotic mini pump model
2006 (ALZET) containing 10 mg/kg per day allosamidin in
0.1 N acetic acid or 0.1 N acetic acid as a control vehicle, and
given the Western diet containing 40% w/w fat and 0.15%
cholesterol (KBT Oriental Co, Ltd.) for 6 weeks. Blood was
taken every 3 weeks for lipid analysis and chitinase activity
measurement in circulation. Systolic blood pressure and heart
rate were evaluated by the tail-cuff method. The mice were
maintained in the animal facilities at Kyushu University. Theajp.amjpathol.org - The American Journal of Pathology
Role of Chitinase in Atherosclerosisstudy protocol was reviewed and approved by the Committee
on the Ethics of Animal Experiments at Kyushu University
Graduate School of Medical Sciences.Analysis of Atherosclerosis and Other Measurements in
Plasma
Mice were euthanized after 6 weeks of Western diet and
perfused via the left ventricle with 10 mL PBS (n Z 6 per
group). The heart and aortic tree were dissected. Aortic
roots were ﬁxed in 4% paraformaldehyde and 5% sucrose,
and embedded in OCT compound. The aortas were ﬁxed in
10% formaldehyde overnight. Atherosclerotic lesions of the
aortic sinus, as well as the entire length of the aorta, were
analyzed as previously described.11 Frozen sections (6 mg)
of the aortic sinus were prepared, and the sections were used
for detecting lipid (0.5% Oil Red O; Sigma-Aldrich),
macrophages (mac-3, 1:1000; Pharmingen, San Diego,
CA), and T cells (CD4, 1:100; Pharmingen) in the lesion.
The atherosclerotic lesion stained with Oil Red O was
quantitated using a computer-assisted imaging system
(ImageJ version 1.41; NIH, Bethesda, MD). Lesion cell
contents were determined by measuring the absolute posi-
tive area (macrophages) in the aortic sinus, or by counting
the cells (T cells) in the intimal lesions. The plasma samples
collected from the dorsal pedal vein of the mice were used to
measure plasma total cholesterol and triglyceride levels to
see whether allosamidin had an effect on these circulating
lipids, as well as for plasma chitinase activity.Statistical Analysis
Results are given as means  SEM. Statistical analysis was
performed by unpaired Student’s t-test and one-way analysis
of variance in comparing the differences between two
groups and among multiple groups, respectively. A P value
< 0.05 was considered signiﬁcant.Results
CHIT1 Expression Correlates with Atherosclerotic
Lesion Area in Cynomolgous Monkeys
We previously reported that statin or antieMCP-1 therapy
resulted in regression and stabilization of atherosclerotic
lesions, independent of cholesterol levels in nonhuman
primates.12 In this experiment, DNA microarray assay was
performed with mRNA from atherosclerotic lesions of
descending aorta to explore atherosclerosis-related genes,
and CHIT1 was found to be one of 11 candidate genes that
were closely correlated with treatment with pravastatin and
7ND transfection. Real-time PCR results conﬁrmed that
CHIT1 mRNA expression was reduced in pravastatin or
7ND-treated group (Supplemental Figure S1A). Further-
more, CHIT1 mRNA expression was also highly correlatedThe American Journal of Pathology - ajp.amjpathol.orgwith areas of macrophage inﬁltration in the atherosclerotic
lesions of abdominal aortas (Supplemental Figure S1B).
CHIT1 Expression Is Upregulated by
Pro-Atherosclerotic Stimuli in BMDM
IFN-g, TNFa, andLPSare reported to increaseCHIT1mRNA
expression.13 To examine whether other pro-atherosclerotic
stimuli upregulate CHIT1 mRNA expression, BMDM were
treated with Ac-LDL, AGE-BSA, MCP-1, LPS, or IFN-g.
Although stimulation with Ac-LDL, AGE-BSA, LPS, and
IFN-g increased CHIT1 mRNA expression, MCP-1 had no
effect on CHIT1 mRNA expression (Figure 1A).
Chitinase Inhibition Increases Pro-Inﬂammatory
Cytokine Expression in Macrophages and Polarizes
Macrophages into a M1 Phenotype
We used allosamidin to inhibit CHIT1 in vitro and in vivo.
Chitinase activity was suppressed by allosamidin in a dose-
dependent manner, with 10 mmol/L of allosamidin sup-
pressing chitinase activity by more than 90% in vitro
(Supplemental Figure S2). Because inﬂammation is one of
the most important factors in the pathogenesis of athero-
sclerosis, we investigated the effects of allosamidin on
pro-inﬂammatory cytokine expression in macrophages.
Allosamidin treatment increased MCP-1 and TNFa mRNA
expression in RAW264.7 macrophages, but did not change
CCR2 expression (Figure 1B). To determine whether these
changes were mediated via activation of transcriptional
factors, we performed electromobility shift assay and reporter
gene assay for AP-1 and NF-kB, and found that transcrip-
tional activities of both AP-1 and NF-kB were modestly
increased by allosamidin treatment (Figure 2,A and B). We
also investigated whether allosamidin would inﬂuence
macrophage polarization. Expression of M1 markers,
inducible nitric oxide synthase, IL-6, and IL-1b, were
increased, whereas expression of a M2 marker, Arg1, was
decreased by chitinase inhibition (Figure 1B). Although not
statistically signiﬁcant, allosamidin treatment tended to
decrease another M2 marker, Fizz1 expression, but raised IL-
10 expression (Figure 1B). Collectively, these trends indicate
that CHIT1 in its uninhibited state would favor M2
polarization.
Allosamidin Decreases Cholesterol Uptake and Efﬂux in
Macrophages
Because lipid-laden macrophages also play an important
role in the pathogenesis of atherosclerosis, we investigated
the effects of allosamidin on cholesterol metabolism in
macrophages. Allosamidin treatment decreased ATP-
binding cassette transporter A1 (ABCA1), ATP-binding
cassette transporter G1 (ABCG1), scavenger receptor AI
(SR-AI), and CD36 mRNA expression in RAW264.7 cells
(Figure 3A). Peroxisome proliferator-activated receptor g317
Figure 1 A: Chitinase activity increased in BMDM treated with Ac-LDL, AGE-BSA, LPS, and IFN-g. BMDM from C57BL/6 mice were isolated and stimulated with
50 mg/mL AcLDL, 100 ng/mL MCP-1, 100 ng/mL LPS, 100 mg/mL AGE-BSA, or 100 units/mL IFN-g. After 24 hours of stimulation, chitotriosidase activity in the
media was measured as described in Materials and Methods. B: Chitinase inhibitor modiﬁes expression of pro-inﬂammatory cytokines and polarizes macrophages
intoM1phenotype. RAW264.7macrophageswere treatedwithmediumaloneor 10mmol/L allosamidin for 24hours before RNA isolation. Transcripts for TNFa, MCP-
1, CCR2, inducible nitric oxide synthase, IL-6, IL-12p35, IL-1b, Arg1, FIZZ1, and IL-10 were quantiﬁed by real-time PCR. Results are representative of at least three
independent experiments and values are expressed as fold change in abundance (means  SEM). *P < 0.05, **P < 0.01 versus control.
Kitamoto et al(PPARg) and liver X receptor a (LXRa) expressions were
also suppressed by allosamidin treatment (Figure 3A).
In accordance with these results, allosamidin suppressed
receptor-speciﬁc binding and uptake of acLDL (Figure 3B).
Moreover, cholesterol efﬂux assay showed that ApoAI-
speciﬁc cholesterol efﬂux was signiﬁcantly decreased by
allosamidin treatment (Figure 3C). HDL-speciﬁc cholesterol
efﬂux tended to decrease, although not signiﬁcantly, and the
increase in percentage of HDL-speciﬁc efﬂux was signiﬁ-
cantly reduced by allosamidin treatment (Figure 3C).
The Effects of Speciﬁc CHIT1 Inhibition and CHIT1
Overexpression Resemble that of Allosamidin in
Primary Macrophages
To elucidate whether the allosamidin treatment would
have similar effects in primarymacrophages as in RAW264.7
cells, we treated BMDM with allosamidin  IFN-g stimula-
tion. To inhibit CHIT1 mRNA expression speciﬁcally, we
also transfected thioglycollate-elicited peritoneal macro-
phages with siRNA against CHIT1. We used peritoneal
macrophages in this experiment because the high CHIT1
expression in BMDM made it difﬁcult to be inhibited by
siRNA transfection. CHIT1mRNAexpressionwas decreased
by approximately 60% after CHIT1 siRNA transfection
(Supplemental Figure S3A). We also transfected BMDM
with pcDNA3.1-CHIT1 plasmid to investigate whether318CHIT1 overexpression would have the opposite effect to
allosamidin treatment or CHIT1 siRNA transfection. Chiti-
nase activity was increased by approximately 40% after
CHIT1 plasmid transfection (Supplemental Figure S3B).
With cytokine/chemokine gene expression, allosamidin
treatment had similar effects in BMDM as in RAW264.7
cells, especially when stimulated with IFN-g (Figure 4).Most
of the genes related to cholesterol metabolism were also
signiﬁcantly reduced by allosamidin in BMDM (Figure 5).
CHIT1 siRNA transfection tended to resemble the effects
of allosamidin in cytokine/chemokine gene expression
(Figure 4) and signiﬁcantly reduced ABCA1, ABCG1,
PPARg, and LXRa expression, but CD36 and SR-AI mRNA
expression were not changed (Figure 5). Although CHIT1
transfection experiments yielded mostly opposite cytokine/
chemokine gene expression results compared to allosamidin
treatment (Figure 4), only ABCA1 mRNA expression was
signiﬁcantly increased among the genes related to cholesterol
metabolism.
Allosamidin Treatment Promotes Atherosclerosis in
ApoE-Deﬁcient Hyperlipidemic Mice
When we evaluated CHIT1 mRNA expression in the
atherosclerotic aortas of ApoE knockout mice, CHIT1
mRNA expression tended to decrease in the mice fed
a high-fat diet with angiotensin II infusion compared to theajp.amjpathol.org - The American Journal of Pathology
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Figure 2 Chitinase inhibitor increases AP-1 and NF-kB transcriptional
activity. A: RAW264.7 macrophages were treated with medium alone or
10 mmol/L allosamidin overnight. Nuclear protein was extracted and
transcriptional activity of AP-1 and NF-kB were accessed by electro-
mobility shift assay. B: RAW264.7 macrophages were transfected with
AP-1 or NF-kB promotereluciferase plasmid and 2 mg of b-galactosidase
gene driven by SV40 promoter-enhancer sequence. The cells were then
treated with medium alone or 10 mmol/L allosamidin overnight, and
luciferase activity and b-galactosidase were measured. *P < 0.05 versus
control.
Role of Chitinase in Atherosclerosismice fed a chow diet (Figure 6A). To investigate the role of
CHIT1 in the pathogenesis of atherosclerosis, we sponta-
neously treated hyperlipidemic ApoE-deﬁcient mice with
allosamidin, while feeding them the Western diet for 6
weeks. Because allosamidin has been reported to inhibit
chitinase activity at doses as low as 1 mg/kg in vivo,14 we
treated the mice with 1 mg/kg per day using the Alzet
osmotic mini pump model 2006 (ALZET). Plasma chitinase
activity was suppressed by approximately 40% during the
experiment (data not shown) and just before euthanasia
(Figure 6B). There were no signiﬁcant differences in body
weight change, blood pressure, heart rate, and plasma lipid
proﬁle between the control and allosamidin-treated group
(Table 2 and Supplemental Figure S4). Administration of
allosamidin aggravated atherosclerotic lesion area in the
aortic arch (Figure 6C). There was very little plaque
formation in the rest of the aortas for both groups. The
atherosclerotic lesion area and macrophage inﬁltration
area in the aortic sinus were also increased by allosamidinThe American Journal of Pathology - ajp.amjpathol.orgtreatment (Figure 6D). There were very few inﬁltrated T
lymphocytes in the plaque with no statistical difference
between the two groups (Figure 6D).Discussion
Several studies, including ours, have found that chitinase
activity is increased in the sera and plaque tissue of athero-
sclerosis patients and nonhuman primates.4,5,15 However, it
has not been demonstrated whether there is a correlation
between chitinase activity and the pathogenesis of athero-
sclerosis. Because CHIT1 is abundantly produced by acti-
vated macrophages, and because macrophages play an
important role in the pathogenesis of atherosclerosis,1,16 we
sought to determine the effects of CHIT1 on macrophage
function related to atherosclerosis. We used allosamidin to
inhibit chitinase activity and investigated whether allosami-
din modulates production of pro-inﬂammatory cytokines and
cholesterol metabolism in macrophages using both cultured
cells and an in vivo atherosclerosis model. We also inhibited
CHIT1 gene expression by CHIT1 siRNA transfection and
overexpressed CHIT1 protein by transfection of a CHIT1
expression vector to evaluate the speciﬁc role of CHIT1. Our
data suggest that CHIT1 regulates atherosclerotic develop-
ment by mediating: i) pro-inﬂammatory cytokine produc-
tions, ii) macrophage polarization, and iii) cholesterol uptake
and efﬂux in macrophages.
Chitinase activity is reported to be elevated in athero-
sclerosis patients and is correlated to atherothrombotic
stroke and ischemic heart disease.4,5,15,17,18 Serum chitinase
activity is also increased in several human lysosomal lipid
storage diseases including Gaucher disease and Niemann-
Pick disease. It has been proposed as an indicator of
disease severity acting as a biochemical marker of macro-
phage accumulation and activation.19e22 In all of these
diseases, including atherosclerosis, the common theme is
abnormal lipid-laden macrophage accumulation in tissues
and robust secretion of CHIT1 protein.19 CHIT1 mRNA
expression is further increased by stimulation with TNFa,
IFN-g, and LPS.13,23 Oxidized low density lipoprotein also
upregulates chitinase-3-like protein 1 (gp-39) and CHIT1 in
cultured macrophages whereas nonmodiﬁed LDL does
not.24 Our results show that Ac-LDL, as well as IFN-g and
LPS, increased chitinase activity in BMDM, implicating that
lipid accumulation and pro-inﬂammatory cytokine stimula-
tion may induce upregulation of CHIT1 expression in
atherosclerotic lesions. Additionally, AGE-BSA also in-
creased chitinase activity in the current study, indicating that
the hyperglycemic state, such as diabetes mellitus, may
increase CHIT1 expression as well.
There are two major types of macrophage activation: one
that promotes inﬂammation (referred to as classically acti-
vated, or M1), and the other that promotes resolution
(referred to as alternatively activated, or M2).25 An imbal-
ance of their activation status can inﬂuence lipid metabolism,319
Figure 3 Chitinase inhibitor modiﬁes expression of genes related to cholesterol metabolism and decreases cholesteryl ester uptake and cholesterol efﬂux
in macrophage. A: RAW264.7 macrophages were treated with medium alone or 10 mmol/L allosamidin for 24 hours before RNA isolation. Transcripts for ABCA1,
ABCG1, CD36, SR-AI, PPARg, and LXRa were quantiﬁed by real-time PCR. *P < 0.05 versus control. B: Chitinase inhibitor lowers cholesteryl ester uptake by
RAW264.7 cells. Cells were treated with or without allosamidin overnight followed by incubation of Dil-AcLDL at 10 mg/mL in medium for 2 hours at 37C.
Intensity of ﬂuorescence was determined by either confocal microscopy or ﬂow cytometry. C: Chitinase inhibitor decreases apoAI and HDL-mediated
cholesterol transport. RAW264.7 cells were labeled with 3H-cholesterol for 36 hours in the presence or absence of 10 mmol/L allosamidin. ApoAI- or HDL-
dependent or independent cholesterol efﬂux was measured by incubating [3H] cholesterol-labeled RAW264.7 cells with or without apoAI or HDL. Radioac-
tivity in the media was determined as a percentage of total radioactivity in the cells and media (nZ 3; means  SEM). *P < 0.05, **P < 0.01 versus control.
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Figure 4 Chitinase inhibition, CHIT1 inhibition, and CHIT1 overexpression modify pro-inﬂammatory cytokines and polarize primary macrophages toward
a M1 phenotype. BMDM were treated with medium alone or 10 mmol/L allosamidin for 24 hours and were stimulated with or without 10 units/mL IFN-g for 6
hours before RNA isolation. Thioglycollate-elicited peritoneal macrophages were transfected with siRNA against mouse CHIT1 or nontargeting siRNA using
lipofectamine siRNA maximum. After 48 hours of transfection, the cells were harvested for mRNA isolation. BMDM were also transfected with control pcDNA3.1
or pcDNA3.1-CHIT1 plasmid by electroporation (MicroPorator MP-100). After 48 hours of transfection, the cells were stimulated with or without 10 units/mL
IFN-g for 6 hours and harvested for mRNA isolation. Transcripts for TNFa, MCP-1, inducible nitric oxide synthase, IL-6, IL-12p35, IL-1b, Arg1, FIZZ1, and IL-10
were quantiﬁed by real-time PCR. The results are representative of at least three independent experiments and values are expressed as fold change in
abundance (means  SEM). PM4, thioglycollate-elicited peritoneal macrophages. *P < 0.05, **P < 0.01 versus control.
Role of Chitinase in Atherosclerosis
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Figure 5 Chitinase inhibition, CHIT1 inhibition, and CHIT1 overexpression modify expression of genes related to cholesterol metabolism in primary
macrophages. Transcripts for ABCA1, ABCG1, CD36, SR-AI, PPARg, and LXRa were quantiﬁed by real-time PCR. The results are representative of at least three
independent experiments and values are expressed as fold change in abundance (means  SEM). PM4, thioglycollate-elicited peritoneal macrophages. *P <
0.05, **P < 0.01 versus control.
Kitamoto et alinﬂammatory responses, and plaque stability, and thus can
affect the progression and complication of atherosclerosis.26
Because T helper-2 cytokines, such as IL-10, can shift the
balance in favor of M2 macrophages and have beneﬁcial
effects on atherosclerosis, M2 polarization is thought to be
atheroprotective.11,25,27e29 Gaucher cells, which display322elevated CHIT1 expression in response to lipid accumula-
tion, resemble anti-inﬂammatory M2 macrophages.30 Inter-
estingly, another member of the chitinase family, the acidic
mammalian chitinase, is reported to mediate T helper-2-
speciﬁc, IL-13-induced asthma.14 Taken together, these
ﬁndings implicate CHIT1 as a mediator of M2 macrophageajp.amjpathol.org - The American Journal of Pathology
Figure 6 Chitinase inhibitor reduces athero-
sclerotic lesions in spontaneous ApoE-deﬁcient
hyperlipidemic mice fed a Western diet. A: CHIT1
mRNA expression in atherosclerotic aortas of ApoE-
deﬁcient mice fed a chow diet or high-fat diet with
1.9 mg/kg per day infusion of angiotensin II for 4
weeks. The descending aortas were harvested and
total mRNA was extracted. CHIT1 mRNA expression
was evaluated by real-time RT-qPCR (nZ 7 in control
group;nZ 8 in high-fat dietþ angiotensin II group;
means  SEM). B: The 12-week-old mice were
implanted with an osmotic mini pump model 2006
(ALZET) containing 10 mg/kg per day allosamidin or
control vehicle, and fed a Western diet for 6 weeks.
Serum chitinase activity was measured before and
after 6 weeks of allosamidin treatment. Allosamidin
administration suppressed serum chitinase activity
by approximately 40%. C: Aortas (aortic arch to the
iliac bifurcation) from control and allosamidin-
treated mice fed the atherogenic diet for 6 weeks
were opened and stained en face with Oil Red O
(Sigma-Aldrich). Representative images of the aortas
showing the surface plaque (top) and quantiﬁcation
of surface area occupied by lesions in the aortic arch
(bottom left) and the descending aortas (bottom
right) are shown. Data (percentage of area occupied
by lesions) are expressed as means  SEM for each
group. D: Aortic sinus atherosclerosis in control and
allosamidin-treated mice. Atherosclerotic lesion in
the aortic sinus from cryosections was stained with
Oil RedO and counterstainedwithH&E. Sectionswere
also stainedwithMac-3 or CD4 antibody coupledwith
horseradish peroxidase-labeled secondary antibody
and counterstained with hematoxylin to identify the
macrophages and T lymphocytes present in the aortic
sinus lesions. Representative images for each stain-
ingare shown. The atherosclerotic lesionarea stained
with Oil Red O and the macrophage inﬁltration area
stained with Mac-3 antibody were quantitated using
a computer-assisted imaging system. *P < 0.05.
Table 2 Various Measurements in Mice Treated with Allosamidin
versus Control Mice
Control Allosamidin
n 6 6
Body weight, g 36.9  1.2 35.8  2.4
BP, mmHg 115/67  4.8/8.3 115/71  5.2/9.9
HR, bpm 588  47 597  44
Plasma total
cholesterol, mg/dL
908.6  76.8 929.8  114.4
Plasma total
triglycerides, mg/dL
134.0  34.1 140.4  38.1
No measurements were statistically signiﬁcant.
Role of Chitinase in Atherosclerosisphenotype and T helper-2 response. In agreement with this,
our data show that allosamidin treatment increased the
expression of M1 markers and decreased the classic M2
marker, suggesting that CHIT1 polarizes macrophages into
the anti-atherosclerotic M2 phenotype.
Cholesterol homeostasis within macrophages is deter-
mined by the balance between the uptake of modiﬁed lipids
via the scavenger receptors SR-A and CD36, and choles-
terol efﬂux via the reverse cholesterol transporters ABCA1
and ABCG1. Overexpression of human SR-A in bone
marrow cells attenuated atherosclerosis in low density
lipoprotein receptor-deﬁcient or ApoE-deﬁcient mice,31,32
whereas SR-A deﬁciency in atherogenic apoE3-Leiden
mice led to more severe and complex atherosclerotic
lesions.33 Loss of lipid uptake via SR-A or CD36 may lead
to the formation of necrotic core within atherosclerotic
lesions.34 These reports suggest that lipid uptake via scav-
enger receptors may be protective against atherosclerosis.
ABCA1 and ABCG1 mediate the critical part of cholesterol
efﬂux from lipid-laden macrophages to HDL choles-
terol.35,36 Patients with Tangier disease (due to loss ofThe American Journal of Pathology - ajp.amjpathol.orgfunctional mutations in the ABCA1 gene) show low serum
HDL cholesterol level, and have a moderately increased risk
for coronary artery diseases.37,38 Similarly, deﬁciency of
either ABCA1 or ABCG1 in atherogenic hyperlipidemic
mice led to massive lipid accumulation in macrophages and
increased atherosclerotic lesions,39,40 suggesting that
cholesterol efﬂux via ABC transporters is anti-atherogenic.
In our study, allosamidin treatment led to decreased SR-AI,323
Kitamoto et alCD36, ABCA1, and ABCG1 expression, which presumably
resulted in suppressed cholesterol uptake and efﬂux from
macrophages, leading to exacerbation of atherosclerosis.
Although a detailed molecular mechanism of the effects
of CHIT1 is not fully elucidated in this study, its effects on
immune response and cholesterol metabolism appear to
involve the PPARg-LXRa pathway. PPARg has anti-
inﬂammatory properties via negative interference with
NF-kB, AP-1, and signal transducer and activator of tran-
scription.41 Furthermore, positive correlation was observed
between PPARg expression and the M2 markers, such as
CD206, CD36, and CC-chemokine 1.42e44 Additionally,
activation of PPARg and/or LXRa upregulates ABCA1 and
ABCG1 expression,35,45 and PPARg agonists curb athero-
sclerosis by inhibiting foam cell formation.46 Because our
data show that expression of PPARg and LXRa is decreased
by allosamidin treatment, it is likely that CHIT1 exerts its
anti-inﬂammatory effects and promotes cholesterol efﬂux
from macrophages via activation of the PPARg-LXRa
pathway. The detailed mechanism of PPARg and LXRa
upregulation by CHIT1 is currently being investigated.
Whereas serum CHIT1 activity is reported to increase in
patients with atherosclerosis and is correlated with the
severity of the disease,4,5,15 at least in the Corsica Island
case-control study of patients with coronary artery disease
and healthy subjects showed that the frequency of loss of
function mutation in CHIT1 gene is not correlated with the
disease.47 Similarly, because the range of serum CHIT1
activity values from control subjects is wide and in many
cases overlaps with those from atherosclerosis patients,5 it
seems that these data do not necessarily indicate that CHIT1
is just a marker of atherosclerosis. Further clinical studies
are required to elucidate the physiological role of CHIT1 in
human atherosclerotic diseases.
There are several limitations in interpreting our study to
speculate CHIT1 functions in atherosclerosis. First, allosa-
midin is a pseudotrisaccharide consisting of two b1,4-linked
N-acetyl allosamine sugars coupled to allosamizoline, which
renders it an effective inhibitor of all members of the chi-
tinase family 18.6,48 Thus, another human chitinase, acidic
mammalian chitinase, as well as family 18 chitinase-like
mammalian proteins without chitinase activity, such as
YM1 and gp-39, were likely inhibited by allosamidin in our
in vivo study. Because expression of gp-39 is also reported
to be strongly upregulated in macrophages in atherosclerotic
lesions,4 it is possible that allosamidin aggravated athero-
sclerotic lesions partly by inhibiting gp-39 function. Also,
due to limitations in allosamidin delivery, atherosclerosis
examined in the current study was not very advanced.
In summary, continuous administration of a chitinase
inhibitor, allosamidin, for 6 weeks increased atherosclerotic
lesions in hyperlipidemic mice. Allosamidin treatment
caused increased expression of pro-inﬂammatory cytokines,
including TNFa and MCP-1, induced M1 macrophage
polarization, and decreased lipid uptake and cholesterol
efﬂux in macrophages via down-regulation of SR-AI, CD36,324ABCA1, and ABCG1 expression. These data suggest that
CHIT1 has a protective role against atherosclerosis, and that
measures taken to enhance the local chitinase activity in
atherosclerotic lesions may provide a novel treatment for
atherosclerosis.
Supplemental Data
Supplemental material for this article can be found at
http://dx.doi.org/10.1016/j.ajpath.2013.04.003.
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